Xencor (NASDAQ:XNCR) Sees Large Volume Increase – Should You Buy?

Xencor, Inc. (NASDAQ:XNCR) shares saw unusually-strong trading volume on Monday . 438,042 shares traded hands during mid-day trading, a decline of 45% from the previous session’s volume of 803,017 shares.The stock last traded at $18.8690 and had previously closed at $17.47.

Analyst Ratings Changes

Several analysts recently commented on the company. JPMorgan Chase & Co. raised their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Wall Street Zen cut Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial cut their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Xencor Stock Performance

The firm has a market capitalization of $1.52 billion, a P/E ratio of -8.93 and a beta of 0.86. The firm’s 50-day moving average is $13.49 and its 200 day moving average is $12.84.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The firm had revenue of $4.52 million for the quarter, compared to the consensus estimate of $27.86 million. During the same quarter last year, the company posted ($0.66) EPS. Xencor’s revenue for the quarter was down 86.2% on a year-over-year basis. As a group, research analysts expect that Xencor, Inc. will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

A number of large investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xencor during the 4th quarter worth approximately $81,000. Tower Research Capital LLC TRC boosted its holdings in Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in Xencor during the second quarter worth $79,000. NorthCrest Asset Manangement LLC acquired a new position in Xencor during the fourth quarter worth $149,000. Finally, Norges Bank bought a new position in Xencor in the fourth quarter valued at $175,000.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.